BMO Capital Starts Regulus Therapeutics (RGLS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Cowen Starts Regulus Therapeutics (RGLS) at Outperform
October 31, 2012 8:27 AM EDTCowen initiates coverage on Regulus Therapeutics (NASDAQ: RGLS) with a Outperform.
For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.
Shares of Regulus Therapeutics closed at $5.11 yesterday, with a 52 week range of $4.02-$5.48.... More
